Integrated Diagnostics (IDHC) investor relations material

Executive summary

• Achieved strong operational and financial performance in Q1 2026, withstanding seasonal impacts from Ramadan and Eid.

• Revenue grew 31% year-on-year to EGP 2.1 billion in Q1 2026, driven by a 22% increase in test volumes and a 7% rise in average revenue per test.

• Net profit surged 78% year-on-year to EGP 437 million; adjusted net profit up 36% to EGP 292 million.

• Maintained leadership in Egypt, stable progress in Jordan, turnaround in Nigeria, and ramp-up in Saudi Arabia, with Egypt contributing 85% of total revenue.

• Continued investment in network expansion, radiology, specialized diagnostics, and regional footprint, with 153 new branches added, mainly in Egypt.

Financial highlights

• Gross profit increased 28% year-on-year to EGP 807 million; gross margin was 38.9%.

• EBITDA rose 26% to EGP 611 million, with a margin of 29.5%, impacted by pre-operating expenses and higher marketing.

• Net cash balance at EGP 728 million as of 31 March 2026; interest-bearing debt at EGP 422 million.

• Cost of goods sold rose 33% to EGP 1,266 million; raw materials as share of revenue declined to 18.7%.

• SG&A expenses up 32% to EGP 350 million, stable at 16.9% of revenue.

Outlook and guidance

• 2026 revenue budgeted at EGP 10 billion, with gross profit margin of 43% and EBITDA margin around 30%.

• Saudi Arabia revenue expected at SAR 18 million for 2026, with 10 branches by year-end; three more branches to launch soon.

• Flexibility to increase prices further if currency volatility persists.

• EBITDA margins expected to remain in the early thirties medium term.

• Management remains focused on disciplined expansion, operational efficiency, and deepening specialised diagnostics.